Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Every-2-Week Epoetin Alfa Studied as Initiation Treatment for Chemotherapy-Related Anemia

October 1, 2006
Publication
Article
OncologyONCOLOGY Vol 20 No 11
Volume 20
Issue 11

Study results suggest that 80,000 units of epoetin alfa (Epogen, Procrit) administered once every 2 weeks demonstrated comparable changes in hemoglobin levels and safety in treating chemotherapy-related anemia in patients with nonmyeloid malignancies compared to 40,000 units of epoetin alfa once weekly, the current recommended dosage.

Anemia

Study results suggest that 80,000 units of epoetin alfa (Epogen, Procrit) administered once every 2 weeks demonstrated comparable changes in hemoglobin levels and safety in treating chemotherapy-related anemia in patients with nonmyeloid malignancies compared to 40,000 units of epoetin alfa once weekly, the current recommended dosage. This study, the first of its kind to evaluate an extended initiation dose of epoetin alfa in this population, was presented at the 2006 American Society of Clinical Oncology (ASCO) annual meeting.

The randomized, open-label, multicenter study compared the response of study patients to 80,000 units of epoetin alfa dosed once every 2 weeks with 40,000 units once weekly. The primary endpoint was the comparison of baseline-to-final hemoglobin levels between the two treatment groups. Secondary endpoints included the assessment of hemoglobin response, time to hemoglobin response, transfusion requirements, and safety.

Major Findings

A total of 310 patients with nonmyeloid malignancy were enrolled in the study. At entry, patients had hemoglobin levels less than or equal to 11 g/dL of blood and were scheduled to undergo chemotherapy for a minimum of 12 weeks. The patients were randomly assigned to receive one of the two dosing regimens subcutaneously for up to 12 weeks, with dose modifications to maintain hemoglobin levels at approximately 12 g/dL of blood. Breast, lung, and colorectal cancer were the most common tumor types at study entry. Almost 50% of patients in each group received platinum-containing chemotherapeutic agents.

The average change in hemoglobin levels from the start to the end of the study in the group dosed with 80,000 units every 2 weeks was 1.6 g/dL of blood. This was statistically comparable to the increase of 1.8 g/dL of blood achieved by the group dosed with 40,000 units weekly. Additionally, of the patients dosed once every 2 weeks, 9.6% required a transfusion between day 29 and the end of the study compared with 11.1% in the patients dosed weekly.

Seventeen patients in each treatment group were withdrawn from the study due to adverse events, most of which were related to the patient's underlying cancer or chemotherapy. The most frequently reported adverse events were diarrhea, nausea, and fatigue. Clinically relevant thrombotic vascular events occurred in 8% of patients in each group. Nineteen patients died during the study or within 30 days of the last dose of study drug, all of which were deemed by the investigators to be unrelated to the study drug.

Articles in this issue

Epocrates Helps Clinicians Address Patient Safety Needs
Topotecan in Combination With Cisplatin for the Treatment of Stage IVB, Recurrent, or Persistent Cervical Cancer: Review 1
Treating Advanced Breast Cancer in the Older Woman: Review 2
Treating Advanced Breast Cancer in the Older Woman: Review 1
Exercisers May Have Better Breast Cancer Survival
Cancer Pain Management in the 21st Century: Review 3
FDA Approves Amgen's Panitumumab to Treat Advanced Colon Cancer
New Treatment Produces Long-Term Remission in Follicular Non-Hodgkin's Lymphoma Patients
DoD Awards $10+ Mil Grant to V. Craig Jordan for Research on New Breast Ca Treatment
Topotecan in Combination With Cisplatin for the Treatment of Stage IVB, Recurrent, or Persistent Cervical Cancer: Review 2
Darbepoetin-Prefilled Autoinjector Available for Chemotherapy-Associated Anemia
Topotecan in Combination With Cisplatin for the Treatment of Stage IVB, Recurrent, or Persistent Cervical Cancer: Review 3
Knowledge Is Not Enough
Every-2-Week Epoetin Alfa Studied as Initiation Treatment for Chemotherapy-Related Anemia
Cancer Pain Management in the 21st Century: Review 2
Recent Videos
Acupuncture
Related Content
Advertisement

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Radhika Appaya;Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN
May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.


This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection

ONCOLOGY Staff
June 25th 2025
Article

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.


Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Dori Beeler, PhD;Xin Shelley Wang, MD, MPH;Viraj A. Master, MD, PhD
September 20th 2022
Podcast

Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.


22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

Radhika Appaya;Sherene Loi, MD, PhD;Erica Stringer-Reasor;Jean-Sebastien Frenel;Mattea Reinisch;Ruth M. O’Regan;Michelino De Laurentiis;Yeon Hee Park;Anne O’Dea;Yen-Shen Lu;Valeria Gonzalez;Melissa Gao;Sorcha Waters;Huilin Hu;Binghe Xu
June 24th 2025
Article


23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025
Article

Related Content
Advertisement

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Radhika Appaya;Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN
May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.


This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection

ONCOLOGY Staff
June 25th 2025
Article

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.


Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative Oncology

Dori Beeler, PhD;Xin Shelley Wang, MD, MPH;Viraj A. Master, MD, PhD
September 20th 2022
Podcast

Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.


22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

Radhika Appaya;Sherene Loi, MD, PhD;Erica Stringer-Reasor;Jean-Sebastien Frenel;Mattea Reinisch;Ruth M. O’Regan;Michelino De Laurentiis;Yeon Hee Park;Anne O’Dea;Yen-Shen Lu;Valeria Gonzalez;Melissa Gao;Sorcha Waters;Huilin Hu;Binghe Xu
June 24th 2025
Article


23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025
Article

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.